Search

Pipeline

SY002

SY002 focuses on an undisclosed target X, a critical enzyme in DNA damage repair. The expression of X is scarce in normal cells, while is overexpressed in tumor cells. X shows synthetic lethality with BRCA1/2 mutations or homologous recombination defects. It may have promising therapeutic effects for a broad spectrum of tumors as a single agent or in combination with other chemotherapeutic drugs.


0

ADDRESS

 

8 The Green,Suite A
Dover,Delaware 19901.

ADDRESS

8 The Green,Suite A Dover,Delaware 19901.

CONTACT

 

E-mail:bd@synrx-therapeutics.com
           hr@synrx-therapeutics.com

CONTACT

E-mail:bd@synrx-therapeutics.com
           hr@synrx-therapeutics.com

Copyright © 2022 SynRx Therapeutics,LLC.  All Rights Reserved.  

添加微信好友,详细了解产品
使用企业微信
“扫一扫”加入群聊
复制成功
添加微信好友,详细了解产品
我知道了